

Scientific Program

9:00 Opening

G. Comi, SSIF Scientific Committee Member, Italy

9:10 Welcome and Introduction

D. Bates, UK & F. Zipp, Germany

9:30 The changing epidemiology of MS

P.S. Sorensen, Denmark

10:00 The genetics of MS susceptibility and disease course (Quiz)

B. Cree, USA

10:30 *Coffee break*

11:00 Is the individual disease course in clinical trials predictable? Strengths and pitfalls of data derived from clinical trials

L. Kappos, Switzerland

11:30 Mild/benign MS: myth or reality?

H. Tremlett, Canada

12:00 Discussion

12:30 *Lunch*

14:00 Disease severity subgroups and treatment

X. Montalban, Spain

14:30 Juvenile MS (Case study)

C. Confavreux, France

15:00 Progressive Forms of MS

J. Sastre-Garriga, Spain

15:30 Benefit to risk: the Cornerstone in MS treatments

D. Goodin, USA

16:00 *Coffee break*

16:30 Patients' willingness to take risks (Case study)

P. Rieckmann, Canada

17:00 Factors influencing treatment

M. Sandberg, Sweden

17:30 The real life benefit of DMDs

M. Trojano, Italy

18:00 Discussion

9:00 New oral therapies for the treatment of MS

R. Weissert, Switzerland

9:30 New injectable therapies for the treatment of MS

F. Zipp, Germany

10:00 *Coffee break*

10:30 Improving current MS therapies (Case study)

G. Comi, Italy

11:00 Emerging neuroprotective strategies in MS

G. Martino, Italy

11:30 Concluding remarks

D. Bates, UK